Cellectis - CLLS STOCK NEWS

Cellectis has announced the entry into a warrant agreement and the drawdown of the first tranche of €20 million under a credit facility with the European Investment Bank (EIB). This funding, part of a larger €40 million facility, will support the development of Cellectis’ allogeneic CAR T-cell therapeutic pipeline, including UCART22 and UCART123. The first tranche's disbursement is contingent upon the issuance of warrants and the achievement of clinical milestones, both of which have been met. The warrants issued represent 5% of the company's outstanding shares at an exercise price of €1.92. The agreement includes customary negative covenants, and the total amount will mature in six years.

Cellectis, a clinical-stage biotechnology company, announced important data on its share capital as of February 28, 2023. The total number of shares in capital stands at 55,583,768, while the total number of voting rights is 61,651,088. Cellectis focuses on developing cell and gene therapies using its gene-editing platform, TALEN®, and aims to address significant medical needs in oncology and blood disorders. The company's innovative approaches include off-the-shelf CAR-T treatments. Cellectis is traded on both the Nasdaq Global Market under the ticker CLLS and Euronext Growth as ALCLS.

Cellectis, a clinical-stage biotechnology firm, announced the presentation of preclinical data on its UCARTMUC1 CAR T-cell therapy aimed at treating triple-negative breast cancer during the AACR Annual Meeting on April 14-19, 2023. The company is leveraging its advanced TALEN gene-editing technology to armor CAR T-cells, enhancing their efficacy against tumor microenvironments. This therapy targets the MUC1 antigen, which is overexpressed in many TNBC cases. Dr. Laurent Poirot expressed confidence in the product candidate's potential to address significant medical needs amidst challenges posed by solid tumors.

Cellectis has announced significant developments including a €40 million credit facility from the European Investment Bank and a follow-on equity offering of approximately $25 million to enhance its research and development efforts. Positive preliminary clinical data from the Phase 1 BALLI-01 trial of UCART22 for r/r B-cell ALL showed 60% of patients experienced anti-tumor activity. Additionally, the AMELI-01 trial for UCART123 in patients with r/r AML reported a 25% meaningful response rate. The company maintains a cash position of $95 million as of December 31, 2022, enabling sustained operational funding through 2024.

Cellectis S.A. (NASDAQ: CLLS) reported that its 49.1% subsidiary, Calyxt, Inc. (NASDAQ: CLXT), announced its Q4 2022 financial results. Calyxt plans to merge with Cibus Global in an all-stock transaction, expected to close in Q2 2023. Calyxt's revenue in Q4 2022 was negligible, down from $1.9 million in Q4 2021, mainly due to the wind-down of its soybean product line. Operating expenses decreased to $3.4 million from $6.6 million year-over-year. Calyxt's cash position was $3.5 million, and with interim funding from Cibus, it will sustain operations through Q2 2023. The merger aims to enhance synergies and innovation in agricultural gene editing.

Calyxt announced a merger with Cibus Global, aiming to create a leading company in gene editing for agriculture. The all-stock transaction allows Calyxt shareholders to retain approximately 5% ownership post-merger, expected to close in Q2 2023, pending shareholder approval. Financial results for Q4 2022 show nominal revenue of $0, down from $1.9 million in Q4 2021, primarily due to the cessation of the soybean product line, while operating expenses decreased to $3.4 million. Notably, Calyxt has secured interim funding from Cibus to sustain operations through Q2 2023. The company continues to progress on key customer projects and technologies.

Cellectis, a clinical-stage biotechnology company, will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, post-market close. A conference call to discuss these results and business updates is scheduled for March 9, 2023, at 8:00 AM ET. Cellectis focuses on developing innovative cell and gene therapies leveraging its gene-editing technology and aims to provide off-the-shelf CAR-T immunotherapies for oncology. The company is headquartered in Paris, with a presence in New York and Raleigh, and is listed on Nasdaq under the ticker CLLS.

Calyxt, Inc. (Nasdaq: CLXT) has filed a Form S-4 with the SEC regarding its merger with Cibus, a leader in precision gene editing in agriculture. Announced on January 17, 2023, the merger is expected to close in the second quarter of 2023, subject to shareholder approval. Following the merger, the new entity will be named Cibus, Inc. and will trade under the ticker symbol CBUS.

This registration statement includes a preliminary proxy statement and prospectus, providing essential details on the merger and its implications. Investors are urged to review these materials once effective.

Cellectis reported its share and voting rights data for January 31, 2023. The company has a total of 45,675,968 shares in capital and 51,743,288 voting rights. Cellectis specializes in gene-editing technology, focusing on innovative CAR-T therapies for cancer treatment and using its TALEN® platform to develop various therapies. Based in Paris, with operations in New York and Raleigh, Cellectis aims to address unmet medical needs through its leading-edge approaches in cell and gene therapies.